Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.

Authors:
C Even
C Even
Centre Hospitalier Sainte-Anne
France
F Ricci
F Ricci
University of Ferrara
Italy

Invest New Drugs 2019 Apr 6. Epub 2019 Apr 6.

Drug Development Department (DITEP), Institut Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800, Villejuif Cedex, France.

Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who received the dose-escalation-recommended phase 2 dose (RP2D), established previously (Massard C, et al., Annals Oncol 2018, 29:1911-17). Methods Patients with advanced or metastatic cancer, measurable disease, ECOG-PS ≤1, and baseline tumor tissue were enrolled. Primary objectives were to identify a safe RP2D, confirm this dose in expansion cohorts, and document anti-tumor activity. Secondary objectives included safety and progression-free survival (PFS). The ACC expansion cohort received the RP2D regimen of 50 mg crenigacestat thrice per week in a 28-day cycle until disease progression or other discontinuation criteria were met. Results Twenty-two patients with ACC were enrolled in the expansion cohort (median age of 60 years). Median treatment duration was 3 cycles with 6 patients remaining on treatment. There were no objective responses; 1 (5%) patient had an unconfirmed partial response. Disease control rate was 73% and 4 patients had stable disease ≥6 months. Median PFS was 5.3 months (95%CI: 2.4-NE)) for the 22 patients; and 7.7 months (95%CI: 4.0-NR) and 2.4 months (95%CI: 1.1-NE) in the subgroup of patients in second-line (n = 7) or ≥ third-line (n = 9), respectively. Frequent treatment-related-adverse events (all grades) included diarrhea, fatigue, vomiting, decreased appetite, dry mouth, and dry skin. There were no new safety signals. Conclusion The crenigacestat RP2D regimen induced manageable toxicity and limited clinical activity, without confirmed responses, in heavily pretreated patients with ACC.

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-019-00739-x
Publisher Site
http://dx.doi.org/10.1007/s10637-019-00739-xDOI Listing
April 2019
12 Reads

Publication Analysis

Top Keywords

expansion cohort
16
rp2d regimen
8
crenigacestat ly3039478
8
advanced metastatic
8
phase trial
8
notch inhibitor
8
adenoid cystic
8
anti-tumor activity
8
patients acc
8
clinical activity
8
patients
8
cystic carcinoma
8
expansion
5
fatigue vomiting
4
crenigacestat thrice
4
regimen 50 mg
4
received rp2d
4
safety
4
cohort received
4
50 mg crenigacestat
4

References

(Supplied by CrossRef)
Article in Lancet Oncol
SA Laurie et al.
Lancet Oncol 2011
Article in Br J Cancer
PC Thuss-Patience et al.
Br J Cancer 2011
Article in Science
S Artavanis-Tsakonas et al.
Science 1999
Article in Cancer Biol Ther
EJ Allenspach et al.
Cancer Biol Ther 2002
Article in Ann Diagn Pathol
D Bell et al.
Ann Diagn Pathol 2014
Article in J Clin Invest
HF Frierson Jr et al.
J Clin Invest 2013
Article in J Clin Oncol
T Hayashi et al.
J Clin Oncol 2013
Article in Nat Genet
AS Ho et al.
Nat Genet 2013
Article in J Clin Invest
PJ Stephens et al.
J Clin Invest 2013
Article in J Clin Oncol
NG Yousif et al.
J Clin Oncol 2012
Article in Nat Rev Cancer
F Radtke et al.
Nat Rev Cancer 2003

Similar Publications